NYSE · RVTY
Revvity, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RVTY: Nov 03, 2026
Revvity, Inc. Common Stock is expected to report earnings on 11/03/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $1.29. The reported EPS for the same quarter last year was $1.18.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $1.29 | $1.30 | $1.27 | 6 |
| Dec 2026 | $1.62 | $1.65 | $1.61 | 5 |
| Mar 2027 | $1.28 | $1.35 | $1.19 | 3 |
| Jun 2027 | $1.53 | $1.53 | $1.52 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks- Zacks · Oct 29, 11:06 AM EDTGRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive GrowthGRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
- Zacks · Oct 28, 9:27 AM EDTEnvista Q3 Earnings Ahead: Product Innovation to Drive GrowthNVST's Q3 earnings may have gained from Spark aligner growth, new product launches and improving margins. Can innovation drive another earnings beat?
- Zacks · Oct 28, 9:00 AM EDTCharles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 27, 11:10 AM EDTWill Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks · Oct 27, 9:00 AM EDTRevvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseRevvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 27, 8:21 AM EDTHenry Schein to Report Q3 Earnings: Here's What You Should KnowHSIC gears up for Q3 earnings with revenue growth expected across its three segments, fueled by dental products, specialty demand and cloud-based technology.
- Zacks · Oct 26, 8:58 AM EDTCareDx to Report Q3 Earnings: Transplant Testing Growth in FocusCareDx's Q3 earnings are in focus as transplant testing growth, stronger reimbursement and oncology expansion drive revenue prospects despite potential margin pressures.
- Zacks · Oct 23, 10:40 AM EDTELV vs. RVTY: Which Stock Is the Better Value Option?ELV vs. RVTY: Which Stock Is the Better Value Option?
- Zacks · Oct 23, 7:19 AM EDTHere's How IDEXX Laboratories Is Placed Ahead of Q3 EarningsIDXX heads into Q3 earnings with expected revenue and EPS growth, fueled by CAG Diagnostics momentum, higher testing volumes and software gains.
- Zacks · Oct 22, 9:34 AM EDTRevvity Launches Signals LabGistics to Coordinate Scientific WorkflowsRVTY's AI-first Signals LabGistics aims to streamline scientific workflows, enhance R&D-to-manufacturing coordination and expand software growth opportunities.
- Zacks · Oct 22, 8:08 AM EDTAlign Technology to Report Q3 Earnings: What's in the Cards?ALGN's Q3 earnings may benefit from Clear Aligner growth and digital innovations, while capital equipment market challenges could weigh on results.
- Zacks · Oct 21, 8:28 AM EDTLabcorp Prepares to Report Q3 Earnings: What's in the Cards?LH's Q3 earnings may benefit from strong diagnostics demand, specialty testing expansion and acquisitions, with revenues projected to grow 5.7%.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Revvity, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.